Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:KRBPNASDAQ:NCNAOTCMKTS:PPCBNASDAQ:TFFP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKRBPKiromic BioPharma$1.16$0.16▼$3.32$330K1.6611,347 shs107,749 shsNCNANuCana$0.06-2.5%$0.15$0.03▼$10.79$330K1.4237.87 million shs43.43 million shsPPCBPropanc Biopharma$4.25+2.4%$3.91$1.25▼$145.46$80K2.521,777 shs2,353 shsTFFPTFF Pharmaceuticals$0.07$0.06$0.06▼$3.23N/A0.98949,778 shsN/A7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKRBPKiromic BioPharma0.00%0.00%0.00%0.00%-90.54%NCNANuCana0.00%-35.86%+39.49%-93.03%-98.00%PPCBPropanc Biopharma0.00%+2.41%-23.84%-19.05%+386,263.64%TFFPTFF Pharmaceuticals0.00%0.00%0.00%0.00%-96.41%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationKRBPKiromic BioPharmaN/AN/AN/AN/AN/AN/AN/AN/ANCNANuCana2.5249 of 5 stars3.32.00.00.01.12.51.3PPCBPropanc BiopharmaN/AN/AN/AN/AN/AN/AN/AN/ATFFPTFF PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKRBPKiromic BioPharma 0.00N/AN/AN/ANCNANuCana 2.50Moderate Buy$25.0045,272.05% UpsidePPCBPropanc Biopharma 0.00N/AN/AN/ATFFPTFF Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKRBPKiromic BioPharmaN/AN/AN/AN/A($8.29) per shareN/ANCNANuCanaN/AN/AN/AN/A$1.34 per shareN/APPCBPropanc BiopharmaN/AN/AN/AN/A($493.34) per shareN/ATFFPTFF Pharmaceuticals$730K0.40N/AN/A$4.04 per share0.02Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKRBPKiromic BioPharma-$26.90M-$3.50N/AN/AN/AN/AN/A-277.46%N/ANCNANuCana-$24.28M-$7.02N/AN/AN/AN/A-319.85%-88.55%8/13/2025 (Estimated)PPCBPropanc Biopharma-$1.82MN/A0.00∞N/AN/A-3,652.66%-971.09%N/ATFFPTFF Pharmaceuticals-$21.24M-$6.44N/A∞N/AN/AN/AN/AN/ALatest PPCB, NCNA, KRBP, and TFFP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/2/2025Q1 2025NCNANuCana-$0.0129-$0.63-$0.6171-$0.63N/AN/A5/15/2025Q3 2025PPCBPropanc BiopharmaN/A-$12.50N/A-$12.50N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthKRBPKiromic BioPharmaN/AN/AN/AN/AN/ANCNANuCanaN/AN/AN/AN/AN/APPCBPropanc BiopharmaN/AN/AN/AN/AN/ATFFPTFF PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKRBPKiromic BioPharmaN/A0.160.22NCNANuCanaN/A1.251.25PPCBPropanc Biopharma0.012.242.24TFFPTFF PharmaceuticalsN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKRBPKiromic BioPharma10.91%NCNANuCana44.00%PPCBPropanc BiopharmaN/ATFFPTFF Pharmaceuticals15.25%Insider OwnershipCompanyInsider OwnershipKRBPKiromic BioPharma20.59%NCNANuCana31.20%PPCBPropanc Biopharma0.10%TFFPTFF Pharmaceuticals4.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKRBPKiromic BioPharma601.57 million1.22 millionNot OptionableNCNANuCana306.08 million4.18 millionNot OptionablePPCBPropanc Biopharma120,00019,000Not OptionableTFFPTFF Pharmaceuticals194.44 million4.24 millionOptionablePPCB, NCNA, KRBP, and TFFP HeadlinesRecent News About These CompaniesTFF Pharmaceuticals approves dissolution planMarch 8, 2025 | uk.investing.comTFF Pharmaceuticals Announces Delisting from Nasdaq and Potential SEC DeregistrationFebruary 6, 2025 | prnewswire.comTFF Pharmaceuticals Inc (TFFP) Stock: A Deeper Look at Its True PotentialDecember 12, 2024 | bovnews.comBThe TFFP Stock Mystery: Why Did TFFP Plunge Today?December 6, 2024 | bovnews.comBTFF Pharmaceuticals Inc (TFFP) Stock: More Robust Than the Numbers Suggest?November 23, 2024 | bovnews.comBStock Shock: The Unpredictable Rise and Fall of TFFP—What’s Driving the Drama?November 20, 2024 | bovnews.comBTFFP Unveiled: The Shocking Truth Behind TFF Pharmaceuticals Inc’s Latest Stock MovementsNovember 19, 2024 | bovnews.comBU.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.70%November 15, 2024 | msn.comTFF Pharmaceuticals (TFFP) Takes a Dark Turn: What’s Next for Investors?November 15, 2024 | bovnews.comBTFF Pharmaceuticals Shares Fall 66%; Company to Wind DownNovember 14, 2024 | marketwatch.comTFF Pharmaceuticals terminates employees, to wind down operationsNovember 14, 2024 | markets.businessinsider.comTFF Pharmaceuticals to Dissolve and Liquidate AssetsNovember 14, 2024 | markets.businessinsider.comTFF Pharmaceuticals, Inc. Announces Termination of Employees and Wind Down of OperationsNovember 14, 2024 | quiverquant.comQTFF Pharmaceuticals Announces It Will Wind Down OperationsNovember 14, 2024 | globenewswire.comTFF Pharmaceuticals (NASDAQ:TFFP) Stock Quotes, Forecast and News SummaryOctober 9, 2024 | benzinga.comTFF Pharmaceuticals (TFFP) Upgraded to Strong Buy: Here's WhyOctober 8, 2024 | zacks.comTFF Pharmaceuticals, Inc.: TFF Pharmaceuticals' Technology Generates Superior Inhalational Dry Powder Formulations for Pulmonary Drug DeliverySeptember 26, 2024 | finanznachrichten.deTFF Pharmaceuticals’ Technology Generates Superior Inhalational Dry Powder Formulations for Pulmonary Drug DeliverySeptember 26, 2024 | markets.businessinsider.comPost-COVID Trends in Biopharma Contract ManufacturingSeptember 25, 2024 | contractpharma.comCThe Yadot Group to Acquire Experiential Agency Socials DallasSeptember 16, 2024 | dallasinnovates.comDNew MarketBeat Followers Over TimeMedia Sentiment Over TimePPCB, NCNA, KRBP, and TFFP Company DescriptionsKiromic BioPharma NASDAQ:KRBPKiromic BioPharma, Inc., a clinical stage biotherapeutics company, utilizes engineered and non-engineered Gamma Delta T cell (GDT) technologies to develop therapies for solid tumors. The company develops Deltacel-01, which is in Phase 1 clinical trial, for patients with non-small cell lung cancer; Isocel in combination with low-dose radiation to treat Mesothelin Isoform 2 positive solid malignancies; ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; Procel in combination with low-dose radiation to treat PD-L1 positive solid malignancies; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1. It has a license agreement with Longwood University; and a research and development collaboration agreement with Molipharma, S.R.L. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.NuCana NASDAQ:NCNA$0.06 0.00 (-2.48%) Closing price 07/3/2025 03:58 PM EasternExtended Trading$0.05 0.00 (-0.36%) As of 07/3/2025 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer, Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer, and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It is also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. The company has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.Propanc Biopharma OTCMKTS:PPCB$4.25 +0.10 (+2.41%) As of 07/3/2025 12:58 PM EasternPropanc Biopharma, Inc., a biopharmaceutical company, develops cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. It offers PRP, a formulation lead product that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes. The company has a research collaboration with University of Jaén that undertakes the research activities for POP1 joint drug discovery program; and a joint research and drug discovery program with Universities of Jaén and Granada to investigate the changes in genetic and protein expression that occur in cancer cells. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.TFF Pharmaceuticals NASDAQ:TFFP$0.06 0.00 (0.00%) As of 04/10/2025TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment and prophylaxis of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It also develops other dry powder products, such as Augmenta human derived monoclonal antibodies for the treatment of COVID-19 disease; and other vaccines. It has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs. TFF Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Fort Worth, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
